U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Bi
Molecular Weight 208.9804
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 3

SHOW SMILES / InChI
Structure of BISMUTH CATION

SMILES

[Bi+3]

InChI

InChIKey=JDIBGQFKXXXXPN-UHFFFAOYSA-N
InChI=1S/Bi/q+3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/international/bibrocathol.html | https://clinicaltrials.gov/ct2/show/NCT01357538 | https://www.drugs.com/international/noviform.html | https://www.ncbi.nlm.nih.gov/pubmed/17003947

Bibrocathol (trade names Noviform and Posiformin) is a well-established topical antiseptic for the treatment of acute eyelid diseases like blepharitis. Eye ointments containing 2 or 5 % bibrocathol and the excipients liquid paraffin, white soft paraffin, and lanolin have been marketed since 1967 for the treatment of eye irritation, chronic blepharitis, and uninfected corneal injuries. Reports of clinical experience with bibrocathol for inflammation of the edge of the palpebra exist since the beginning of the 20th century. Until recently, no controlled, randomized clinical studies according to the guidelines for Good Clinical Practice for Trials on Medical Products for Human Use (GCP) as defined by the International Conference on Harmonisation (ICH) have been performed with bibrocathol 2 % ointment, as these were not required for marketing authorization in the 1960s. A first double-blind, prospective, controlled, GCP-compliant clinical study was recently performed to assess the efficacy of bibrocathol 5 % (Noviform®) in acute blepharitis. It demonstrated superior efficacy of bibrocathol 5 % ointment as compared to an ointment vehicle (placebo) after 2 weeks of treatment as assessed by a combined measure of slit-lamp examination results and patients’ subjective complaints.

Originator

Sources: Medizinische Klinik (Muenchen, Germany) (1913), 8, 992.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Noviform

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Successful treatment of blepharitis with bibrocathol (Posiformin® 2 %).
2012 Dec
Patents

Sample Use Guides

A strip of 5 mm eye ointment applied 3 times per day to the eye lid
Route of Administration: Topical
In Vitro Use Guide
Unknown
Name Type Language
BISMUTH CATION
Common Name English
BISMUTH, ION (BI3+)
Common Name English
BISMUTH CATION (3+)
Common Name English
Classification Tree Code System Code
NDF-RT N0000007888
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
NDF-RT N0000007888
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
WHO-ATC A02BA07
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
NDF-RT N0000180183
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
Code System Code Type Description
PUBCHEM
105143
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
PRIMARY
FDA UNII
ZS9CD1I8YE
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
PRIMARY
CAS
23713-46-4
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
PRIMARY
RXCUI
1546284
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB14572
Created by admin on Sat Jun 26 10:35:37 UTC 2021 , Edited by admin on Sat Jun 26 10:35:37 UTC 2021
PRIMARY